Latest Content

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

Roundtable reveals vitiligo care gaps: Opzelura leads, insurers still call it cosmetic, and pricey oral JAKs near approval—what’s next?

A gene tied to poor sarcoma prognosis also rose fastest in pazopanib-sensitive sarcoma cell lines, a new exploratory study suggests.

A national survey finds retina specialists tolerate higher GA treatment risks in exchange for greater lesion growth rate reduction.

Most eligible people with multiple sclerosis have never used GLP-1 receptor agonists, despite their potential cardiometabolic benefits.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

Higher-performing Medicare accountable care organizations are smaller and characterized by real-time information sharing, regular performance feedback, primary care physician leaders, physician buy-in, and strong care management programs.

This meta-analysis encompassed 18 studies published through December 31, 2025.

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.